CVRS - Corindus Vascular Robotics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.8400
0.0000 (0.00%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.8400
Open2.8500
Bid2.8600 x 1800
Ask2.8700 x 4000
Day's Range2.8200 - 2.9150
52 Week Range0.7100 - 3.1100
Volume398,480
Avg. Volume1,586,860
Market Cap587.028M
Beta (3Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire26 days ago

    Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, PCR Vice-Chairman, and Course Director of EuroPCR, Dr. Jean Fajadet performed the procedure from Clinique Pasteur in Toulouse, France.

  • Business Wire29 days ago

    Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight recent milestones in technology development, including the latest CE marked technIQ™ Smart Procedural Automation, automated movements aimed at improving navigation, lesion crossing, and delivery of therapy.

  • Business Wirelast month

    Corindus Reports First Quarter 2019 Results

    Eleven purchase orders for CorPath GRX Systems as adoption grows

  • ACCESSWIRElast month

    Corindus Vascular Robotics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Corindus Vascular Robotics, Inc. (NYSE American: CVRS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 ...

  • Business Wirelast month

    Corindus Equips the World’s First Fully Robotic Catheterization Laboratory

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital in the world to adopt vascular robotic systems in all vascular intervention treatment rooms. The outfitted labs will allow physicians to leverage the latest robotic technology for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) and provide all patients requiring these procedures at Chesapeake Regional access to the latest technology in cardiovascular disease care.

  • Business Wire2 months ago

    Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S.

  • Business Wire2 months ago

    Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) approval in 2018 and A1 technical fee reimbursement for Japan in March of this year.

  • Business Wire3 months ago

    Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarter, Corindus sold shares of its common stock to a large institutional investor and certain existing stockholders with contractual preemptive rights, including Hudson Executive Capital (“HEC”) and BioStar Ventures, for aggregate gross proceeds of approximately $19.8 million. HEC purchased an amount in excess of their allotment under the preemptive rights.

  • Business Wire3 months ago

    Corindus Reports Fourth Quarter and Full Year 2018 Results

    Submitted Neurovascular Indication Marking Important Step toward Addressing Stroke Market; Raised $19.8 Million to Fund Ongoing Innovation

  • Business Wire3 months ago

    Corindus Vascular Robotics Announces Additional Closing of Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 shares of the Company’s common stock on the same terms and at the same price of $1.3796 per share as the initial closing through the exercise of such preemptive rights and the purchase of certain additional shares. The Company intends to use the proceeds for general corporate purposes.

  • Business Wire3 months ago

    Corindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S.

  • Business Wire3 months ago

    Corindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,

  • Business Wire4 months ago

    Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The Company intends to use the proceeds for general corporate purposes. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state and other jurisdiction.

  • Business Wire4 months ago

    Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).

  • Business Wire6 months ago

    Corindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary Intervention

    CorPath® telerobotic interventional platform has the potential to deliver timely, specialized cardiovascular treatment to remote, underserved patient populations across the globe. Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announces that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, December 4 and 5, 2018, in India.

  • GlobeNewswire7 months ago

    Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire7 months ago

    Corindus to Present at Upcoming 2018 Healthcare Conferences

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that management will present at two investor conferences

  • Business Wire7 months ago

    Corindus Reports Third Quarter 2018 Results

    Advancing Development Programs for Remote Robotics and Neurovascular Applications

  • Business Wire8 months ago

    Corindus to Report Third Quarter Financial Results on November 6, 2018

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S.

  • Business Wire9 months ago

    Corindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018

    Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. In the first case at University of Washington Medical Center, Dr. William Lombardi, a high volume chronic total occlusion (CTO) PCI operator, performed the first live transmission of a hybrid CTO PCI using both manual and robotic techniques to successfully treat a patient suffering from a complete coronary artery blockage.

  • Business Wire9 months ago

    Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 Conference

    Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, CA on September 22, 2018. The remote interventional procedure was broadcast live from Mayo Clinic to the TCT Main Arena. Utilizing CorPath GRX with developmental remote technology, combined with a telecommunications system to enable communication with the bedside staff, the operator at Mayo Clinic had the ability to remotely manipulate interventional devices within a porcine model's arteries while located in a different building.

  • Business Wire9 months ago

    Corindus to Present at Ladenburg Thalmann 2018 Healthcare Conference

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,

  • Business Wire9 months ago

    Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference

    Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical device for robotic-assisted vascular interventions.